Sign up to our newsletter

At HyTest, our specialization in cardiac troponin (cTn) detection spans nearly three decades. Over the years, we have generated and analysed thousands of cTn-specific antibodies.

We're delighted to announce the launch of our latest troponin product: the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex.

We will be attending Medica 2023 in November.

We have been privileged to have Soozy and Linda on our team for about 10 years. Now the story continues with new job descriptions – Soozy Xi will continue as CCO of HyTest and Linda Li will take on the role of General Manager of HyTest China. The whole team warmly congratulates! We also got a few comments from them:

Procalcitonin (PCT) is an established biomarker, which is used to guide antibiotic treatment in septic patient. As an invaluable indicator, it shows high sensitivity and specificity for bacterial infection. Given the utility of PCT in clinical setting, variability in results from different commercial assays have been observed. In this webinar, participants will have the opportunity to review the clinical application of PCT, technology used for PCT measurements and also the challenges in terms of the standardization effort.

#teamhytest is looking forward to meeting our customers at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim!

We are happy to introduce General Manager of HyTest North America Hut Coats. With Hut in our team, we’re able to be closer to our customers in North America and provide even better service.

The EFLM Award Committee had a difficult task in selecting for the most remarkable scientific work among the submitted papers but in the end Rami Aalto, (University of Turku, Finland) was selected to receive the award.

We are pleased to announce that Netta Keinänen, a valued member of our leadership team, will be stepping into the role of CEO on June 5th, 2023. With her experience, leadership, and strategic vision, we are confident that Netta will continue to lead us to even greater success.  

We have launched a new troponin MAb Y302 recombinant monoclonal antibody, which is expressed in a mammalian cell line and contains full-size IgG sequence derived from rabbit B cells and epitope specificity for this MAb is 83 – 100 a.a.r. of human cardiac troponin I.

A new article titled "Fragmentation of human cardiac troponin T after acute myocardial infarction" by our scientists was published in Clinica Chimica Acta journal.

We are launching a new product, recombinant thyroglobulin, Cat # 8RTG4.

Troponin I and T are the main biomarkers and gold standards for diagnostics of acute myocardial infarction (AMI). Recently high- sensitivity cTn (hs-cTn) assays, the detection limit of which is pg/ml (ng/l) rather than ng/ml, have made it possible to identify any myocardial injury, including those AMI patients, within 1 to 3 hours. This represents a potential 3-hour time saving to ensure more rapid patient management.

HF is a severe clinical and public health problem that is characterized by an increasing prevalence and economic cost. NT-proBNP, a derivative of pro-B-type natriuretic peptide (proBNP), is an established biomarker for heart failure (HF) diagnostics.

We will be attending Medlab Middle East 2023 in the beginning of February.

Seasonal flu is an acute respiratory infection caused by influenza viruses, including influenza A and influenza B. The typical symptoms include headaches, running nose, cough and muscle pain. The infection of other respiratory viruses, such as respiratory syncytial virus (RSV), can also present flu-like symptoms.

HyTest offers 5 new antibodies specific for cTnI. The antibodies are specific to epitopes 22-40 (Y306 and Y503), 83-100 (Y101), 161-178 (Y501), and 174-191 (Y502).

We are sponsoring the Cardiac Marker Dialogues meeting.

We will be attending Medica trade show 2022.

Medica 2022, the World Medicine Forum will take place 14-17 November 2022 in Düsseldorf, Germany.

The Award is given to the best published paper, as judged by an independent panel of experts, which demonstrates a remarkable scientific work in the field of cardiovascular diseases.
The Award, consisting of a certificate and a sum of 5,000 Euro,
will be presented to the first author, who is responsible for division among co-authors, at the 25th IFCC-EFLM EuroMedLab Congress to be held in Rome from 21 to 25 May 2023.